OAKVILLE, ON, Feb. 1, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX:CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has paid the second and final installment of its earn-out to Cinven1 relating to Concordia's
Today's payment of Ģ72 million, plus interest of approximately Ģ1.5 million, was paid with cash on hand.
About ConcordiaConcordia is a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs. The Company has an international footprint with sales in more than 100 countries, and has a diversified portfolio of more than 200 established, off-patent molecules that make up more than 1,300 SKUs. Concordia also markets orphan drugs through its Orphan Drugs Division, consisting of PhotofrinŪ for the treatment of certain rare forms of cancer.
Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.
1 In this press release 'Cinven' means, depending on the context, any of or collectively, Cinven Group Limited, Cinven Partners LLP, Cinven (LuxCo1) S.A., Cinven Capital Management (V) General Partner Limited and their respective Associates (as defined in the Companies Act 2006) and/or funds managed or advised by the group.
SOURCE Concordia International Corp.
Subscribe to our Free Newsletters!
Hearing loss calculator is a quick online screening test to check for hearing loss. Result from ...
Home remedies such as baking soda, sugar, Epsom salt, black tea and castor oil exfoliate, soften ...
Immunosuppressant drugs suppress immunity. But why would you want to reduce immunity, which is ...View All